Researchers at Roswell Park Comprehensive Cancer Center have launched a phase 2 clinical trial that they hope will improve both survival and quality of life for patients with recurrent ovarian, fallopian-tube or primary peritoneal cancer and malignant effusion, a side effect of the disease that significantly impairs quality of life. The study is exclusive to Roswell Park, where it was developed.

Following a national search, Roswell Park Comprehensive Cancer Center has promoted Andrew Storer, PhD, DNP, RN, NP-C, FAANP, as Chief Nursing Officer, Senior Vice President for Patient Care Services and Associate Professor of Oncology.

A team at Roswell Park Comprehensive Cancer Center has uncovered a link between survival and the number of tumor-infiltrating lymphocytes (TILs) in the tumors of breast cancer patients. Kazuaki Takabe, MD, PhD, FACS, Clinical Chief of Breast Surgery, Breast Program Leader and Breast Disease Site Leader at Roswell Park, served as principal investigator of the new study published in Annals of Surgery. Rongrong Wu, MD, and Masanori Oshi, MD, of the Department of Surgical Oncology at Roswell Park were first authors of the study, which was completed in collaboration with colleagues in Japan.